Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses

View ORCID ProfileXaquin C Dopico, Leo Hanke, Daniel J. Sheward, Sandra Muschiol, View ORCID ProfileSoo Aleman, View ORCID ProfileNastasiya F. Grinberg, Monika Adori, Murray Christian, Laura Perez Vidakovics, Changil Kim, Sharesta Khoenkhoen, Pradeepa Pushparaj, Ainhoa Moliner Morro, View ORCID ProfileMarco Mandolesi, Marcus Ahl, View ORCID ProfileMattias Forsell, View ORCID ProfileJonathan Coquet, Martin Corcoran, Joanna Rorbach, Joakim Dillner, View ORCID ProfileGordana Bogdanovic, View ORCID ProfileGerald M. McInerney, Tobias Allander, View ORCID ProfileBen Murrell, View ORCID ProfileChris Wallace, View ORCID ProfileJan Albert, View ORCID ProfileGunilla B. Karlsson Hedestam
doi: https://doi.org/10.1101/2020.07.17.20155937
Xaquin C Dopico
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xaquin C Dopico
  • For correspondence: xaquin.castro.dopico@ki.se
Leo Hanke
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel J. Sheward
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Muschiol
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soo Aleman
3Department of Infectious Diseases, Karolinska Universitetssjukhuset, Huddinge 141 52, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Soo Aleman
Nastasiya F. Grinberg
4Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, CB2 0AW
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nastasiya F. Grinberg
Monika Adori
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murray Christian
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Perez Vidakovics
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changil Kim
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharesta Khoenkhoen
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pradeepa Pushparaj
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ainhoa Moliner Morro
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Mandolesi
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marco Mandolesi
Marcus Ahl
3Department of Infectious Diseases, Karolinska Universitetssjukhuset, Huddinge 141 52, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mattias Forsell
5Department of Clinical Microbiology, Umeå Universitet, Umeå 901 85, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mattias Forsell
Jonathan Coquet
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathan Coquet
Martin Corcoran
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Rorbach
6Department of Molecular Biochemistry & Biophysics, Karolinska Institutet, Stockholm 171 77, Sweden
7Max Planck Institute-Biology of Ageing, Karolinska Institutet Laboratory, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joakim Dillner
8Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge 141 52, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordana Bogdanovic
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gordana Bogdanovic
Gerald M. McInerney
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gerald M. McInerney
Tobias Allander
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Murrell
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ben Murrell
Chris Wallace
4Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, CB2 0AW
9MRC Biostatistics Unit, University of Cambridge CB2 0SR, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chris Wallace
Jan Albert
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jan Albert
Gunilla B. Karlsson Hedestam
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gunilla B. Karlsson Hedestam
  • For correspondence: xaquin.castro.dopico@ki.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Antibody responses vary widely between individuals1, complicating the correct classification of low-titer measurements using conventional assay cut-offs. We found all participants in a clinically diverse cohort of SARS-CoV-2 PCR+ individuals (n=105) – and n=33 PCR+ hospital staff – to have detectable IgG specific for pre-fusion-stabilized spike (S) glycoprotein trimers, while 98% of persons had IgG specific for the receptor-binding domain (RBD). However, anti-viral IgG levels differed by several orders of magnitude between individuals and were associated with disease severity, with critically ill patients displaying the highest anti-viral antibody titers and strongest in vitro neutralizing responses. Parallel analysis of random healthy blood donors and pregnant women (n=1,000) of unknown serostatus, further demonstrated highly variable IgG titers amongst seroconverters, although these were generally lower than in hospitalized patients and included several measurements that scored between the classical 3 and 6SD assay cut-offs. Since the correct classification of seropositivity is critical for individual- and population-level metrics, we compared different probabilistic algorithms for their ability to assign likelihood of past infection. To do this, we used tandem anti-S and -RBD IgG responses from our PCR+ individuals (n=138) and a large cohort of historical negative controls (n=595) as training data, and generated an equal-weighted learner from the output of support vector machines and linear discriminant analysis. Applied to test samples, this approach provided a more quantitative way to interpret anti-viral titers over a large continuum, scrutinizing measurements overlapping the negative control background more closely and offering a probability-based diagnosis with potential clinical utility. Especially as most SARS-CoV-2 infections result in asymptomatic or mild disease, these platform-independent approaches improve individual and epidemiological estimates of seropositivity, critical for effective management of the pandemic and monitoring the response to vaccination.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding for this work was provided by a Distinguished Professor grant from the Swedish Research Council (agreement 532 2017-00968) and NIH (agreement SUM1A44462-02). CW and NFG are funded by the Wellcome Trust (WT107881) and MRC (MC_UP_1302/5)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Swedish Ethical Review Authority (registration no. 2020-01807).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data generated as part of the study, along with custom code for statistical analyses, is openly available via our GitHub repositories: https://github.com/MurrellGroup/DiscriminativeSeroprevalence/ and https://github.com/chr1swallace/seroprevalence-paper.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 06, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses
Xaquin C Dopico, Leo Hanke, Daniel J. Sheward, Sandra Muschiol, Soo Aleman, Nastasiya F. Grinberg, Monika Adori, Murray Christian, Laura Perez Vidakovics, Changil Kim, Sharesta Khoenkhoen, Pradeepa Pushparaj, Ainhoa Moliner Morro, Marco Mandolesi, Marcus Ahl, Mattias Forsell, Jonathan Coquet, Martin Corcoran, Joanna Rorbach, Joakim Dillner, Gordana Bogdanovic, Gerald M. McInerney, Tobias Allander, Ben Murrell, Chris Wallace, Jan Albert, Gunilla B. Karlsson Hedestam
medRxiv 2020.07.17.20155937; doi: https://doi.org/10.1101/2020.07.17.20155937
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Probabilistic approaches for classifying highly variable anti-SARS-CoV-2 antibody responses
Xaquin C Dopico, Leo Hanke, Daniel J. Sheward, Sandra Muschiol, Soo Aleman, Nastasiya F. Grinberg, Monika Adori, Murray Christian, Laura Perez Vidakovics, Changil Kim, Sharesta Khoenkhoen, Pradeepa Pushparaj, Ainhoa Moliner Morro, Marco Mandolesi, Marcus Ahl, Mattias Forsell, Jonathan Coquet, Martin Corcoran, Joanna Rorbach, Joakim Dillner, Gordana Bogdanovic, Gerald M. McInerney, Tobias Allander, Ben Murrell, Chris Wallace, Jan Albert, Gunilla B. Karlsson Hedestam
medRxiv 2020.07.17.20155937; doi: https://doi.org/10.1101/2020.07.17.20155937

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4815)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5282)
  • Intensive Care and Critical Care Medicine (326)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (111)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (438)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (128)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (769)
  • Public and Global Health (1799)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)